Skip to main content

What the FDA labels say about taking them together

Abiraterone and repaglinide

Abiraterone's FDA label of March 28, 2025 names repaglinide in its warnings and precautions section; the repaglinide label PlainMeds reads does not name abiraterone. The abiraterone label: “Severe hypoglycemia has been reported in patients with pre-existing diabetes who are taking medications containing thiazolidinediones (including pioglitazone) or repaglinide.”

Check it at the source: the abiraterone FDA label on DailyMed (effective March 28, 2025, Janssen Biotech, Inc.); the repaglinide FDA label on DailyMed (effective May 2, 2025, Chartwell RX, LLC).

What does the abiraterone label say about repaglinide?

Abiraterone label, warnings and precautions

Severe hypoglycemia has been reported in patients with pre-existing diabetes who are taking medications containing thiazolidinediones (including pioglitazone) or repaglinide.

Source: FDA drug label (Zytiga), Janssen Biotech, Inc., effective March 28, 2025 (SPL set 4e338e89-3cf2-48eb-b6e2-a06c608c6513), via openFDA; the full label on DailyMed

What does the repaglinide label say about abiraterone?

Repaglinide's label (effective May 2, 2025) does not name abiraterone in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Repaglinide), Chartwell RX, LLC, effective May 2, 2025 (SPL set cb995e92-295e-4638-a064-978211f5afe1), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

23Abiraterone generic labelers
7Repaglinide generic labelers
AbirateroneRepaglinide
Labeled forProstate cancerType 2 diabetes
Boxed warningNoNo
Pharmacy cost (NADAC)$0.774 per tablet 250 mg tablet$0.0987 per tablet 1 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?